Deutsche Bank lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,500 and keeps a Buy rating on the shares.

Assetmark Inc. boosted its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 16.2% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 82,629 shares of ...

Genmab reported impressive earnings with significant revenue growth driven by its key products, despite rising expenses.

Genmab AS (GMAB) reports a 29% revenue increase and strategic moves in its product pipeline, despite challenges in ...

An influx of late-phase programs has prompted Genmab to reassess its bets. | An influx of late-phase programs has prompted Genmab to reassess its bets. The biotech is axing three early-stage clinical ...

November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY® (e ...

It has been roughly eight months since my last Genmab (GMAB) article, where I highlighted the company's robust pipeline progress, strategic partnerships, and a strong 2023 performance, led by ...

GEN1047, GEN3017, and GEN1056—to refocus resources, following its recent $1.8 billion acquisition of ProfoundBio. The move ...

Hello, and welcome to Genmab's Financial Results Conference Call for the First Nine Months of 2024. As a reminder, this conference call is being recorded. During this telephone conference ...

Denmark stocks were lower after the close on Thursday, as losses in the Real Estate, Personal & Household Goods and ...

Analysts' ratings for Genmab (NASDAQ:GMAB) over the last quarter vary from bullish to bearish, as provided by 10 analysts. The following table provides a quick overview of their recent ratings ...